News Releases

June 2021

June 7, 2021 6/7/2021 Phase 3 Clinical Trial Subgroup Analysis Across SOT Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With CMV Infection

May 2021

May 28, 2021 5/28/2021 Takeda to Hold Oncology Focused Investor Call on June 8

May 22, 2021 5/22/2021 Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results

May 21, 2021 5/21/2021 US Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment

May 21, 2021 5/21/2021 Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan

May 19, 2021 5/19/2021 Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC

May 19, 2021 5/19/2021 Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML

May 11, 2021 5/11/2021 Notice Concerning Issuance of New Shares through Third-Party Allotment associated with Continuation of Stock Grant System for Company Group Management in Japan in Fiscal 2021

May 11, 2021 5/11/2021 Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Group Management in Japan in Fiscal Year 2021